Skip to main content
Sinopharm Tech Holdings Limited logo

Sinopharm Tech Holdings Limited — Investor Relations & Filings

Ticker · 8156 ISIN · KYG2159V1418 HKEX Wholesale and retail trade
Open in API
Filings indexed 1,471 across all filing types
Latest filing 2022-07-07 Regulatory Filings
Country HK Hong Kong
Listing HKEX 8156

About Sinopharm Tech Holdings Limited

http://www.sinopharmtech.com.hk

Sinopharm Tech Holdings Limited is an investment holding company primarily engaged in the big health industry and pharmaceutical supply chain business. The company focuses on the trading and distribution of medical and related products, including Chinese patent medicines and health products, targeting the market in the PRC. It develops its supply chain operations using "Internet Plus" services, leveraging technology to provide value-added services to industry operators and product suppliers. The Group is also integrating AI analytics to enhance its operations within the healthcare sector.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2022
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report concerning movements in securities, including authorized and issued shares, share options, convertible bonds, and confirmations related to securities issued by Sinopharm Tech Holdings Limited. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules, specifically Chapter 19B. The document includes detailed tables of share capital movements, share options, convertible bonds, and confirmations by the company secretary. It is a regulatory submission reporting on share capital and securities movements for the month ended 30 June 2022. It is not an annual or interim financial report, earnings release, or management discussion. It is not a proxy statement, voting results, or a governance report. The document is a regulatory filing reporting share capital and securities movements as required by the stock exchange rules. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-07-07 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2022
Capital/Financing Update Classification · 95% confidence The document is a detailed monthly return report on movements in securities for Sinopharm Tech Holdings Limited, including authorized share capital, issued shares, share options, convertible bonds, and confirmations related to securities issuance. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content focuses on share capital changes, share options, convertible bonds, and confirmations of compliance with listing requirements. This type of document is a regulatory submission related to capital changes and share issuance activities, not a full financial report, earnings release, or management discussion. It is not a simple announcement but a formal regulatory filing detailing capital structure movements. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication notice.
2022-06-07 English
VOLUNTARY ANNOUNCEMENT - POSSIBLE DILUTION OF INTEREST IN AN ASSOCIATE
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by Sinopharm Tech Holdings Limited regarding a possible dilution of interest in an associate due to a fund raising proposal by the associate company. It discusses the background, details of the fund raising, the company's decision not to participate, and the potential impact on shareholding. The document is an announcement informing shareholders and investors about a financing event and its implications, rather than a full financial report or detailed financial statements. It does not contain comprehensive financial data or results but rather updates on capital structure and financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (6280 characters) and content confirm it is not a brief report publication announcement or a regulatory filing. Hence, the classification is CAP with high confidence.
2022-06-07 English
VOLUNTARY ANNOUNCEMENT IN RELATION TO COOPERATION AGREEMENT WITH TENCENT CLOUD
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Sinopharm Tech Holdings Limited regarding a cooperation agreement with Tencent Cloud. It describes the business development and intentions of the parties to explore cooperation opportunities, including product development and blockchain technology applications. There are no financial statements, regulatory certifications, voting results, or management changes reported. The document is an announcement of a business cooperation agreement rather than a financial report, regulatory filing, or other specific report types. It is not a report publication announcement since it contains substantive information about the cooperation. The content fits best under a general regulatory announcement category that does not fit other specific categories.
2022-05-24 English
PROFIT GUARANTEE IN RELATION TO THE ACQUISITION OF THE TARGET COMPANY INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE
Capital/Financing Update Classification · 95% confidence The document is an announcement from Sinopharm Tech Holdings Limited regarding a profit guarantee related to the acquisition of a target company and the issue of consideration shares. It details the background of the acquisition, the non-fulfillment of the guaranteed profit, the resulting compensation arrangement, and the settlement agreement terms. The document includes specific financial figures related to the profit shortfall and compensation but does not contain comprehensive financial statements or a full financial report. It is a regulatory announcement about a financing and acquisition-related matter, specifically addressing the profit guarantee and compensation settlement. It is not an annual report, interim report, earnings release, or audit report. It is also not a merger filing or a management discussion and analysis report. Given the nature of the content—an announcement about a profit guarantee and compensation related to an acquisition and share issuance under a specific mandate—it fits best under Capital/Financing Update (CAP). The document is detailed and substantive, not a brief notice or a report publication announcement, so RPA is not appropriate. Therefore, the classification is CAP with high confidence.
2022-05-23 English
THIRD QUARTERLY REPORT 2021/2022
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "THIRD QUARTERLY REPORT 2021/2022" and contains detailed unaudited consolidated financial results for the three and nine months ended 31 March 2022. It includes comprehensive financial statements such as profit or loss, comprehensive income, notes on accounting policies, revenue breakdown, loss before tax, income tax credit/expense, loss per share, and movements of reserves. The presence of actual financial data and analysis for a period shorter than a full fiscal year (quarterly and nine months) confirms this is a quarterly financial report. The document is not a brief announcement or a certification but a full financial report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2022
2022-05-13 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.